Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide continuing education effort for physicians on the evolving challenges of managing HIV disease. Injectable antiretroviral therapy formulations hold great promise in helping to close the significant gap between efficacy and effectiveness in HIV treatment by eliminating the requirement for lifelong daily pills. With the recent FDA approval, significant challenges to implementation of injectable antiretroviral therapy in HIV treatment are anticipated in the United States. We are fortunate to hear about Dr Klein’s experience in Canada, the first country to approve this treatment. Although these drugs are part of Canada’s system, given the COVID-19 pandemic, it has not been widely implemented. Dr Klein will be joined by Dr Saag in this discussion, where they will review challenges and propose solutions for effective implementation and use of injectable antiretrovirals for HIV treatment.
Note (as of April 29, 2021): The preliminary agenda has been finalized for this webinar and injectable antiretrovirals for prevention, which was previously noted in the title and description, will not be a focus of webinar.
On completion of this webinar, learners will be able to:
- Describe potential benefits of injectable antiretroviral drugs for prevention and treatment of HIV infection
- Describe the potential challenges in implementing treatment with injectable antiretrovirals
- Propose ways to address these challenges and incorporate injectables into clinical practice
Who Should Attendpre
This webinar is designed for clinical decision makers who are actively involved in HIV care and research.
This activity is also relevant for registered nurses, pharmacists, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive continuing education credit or a certificate of participation.
Registration closes on Thursday, May 18, 2021, 9:00 AM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at email@example.com or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.
The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Dr Klein has served as a consultant to and has received grants paid to their institution from ViiV Healthcare, AbbVie, and Gilead Sciences, Inc. (Updated 12/15/20)
Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc, and ViiV Healthcare. (Updated 06/20/20)
All relevant financial relationships have been mitigated.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.25 contact hours (0.125 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-21-240-L02-P
This program is approved for 1.25 hours of pharmacotherapy credit.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co., Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at firstname.lastname@example.org or 415-544-9400.